SEC Form 4 · accession 0000899243-18-029757
Global Blood Therapeutics, Inc. · GBT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jeffrey S Farrow
Officer — Chief Financial Officer
Period of report
Nov 27, 2018
Accepted (ET)
Nov 28, 2018 · 6:01 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001629137
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Nov 27, 2018 | M | 3,048 | $16.40 | A | 15,555 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $16.40 | Nov 27, 2018 | M | 3,048 | D | — | Jan 16, 2027 | Common Stock | 3,048 | 33,952 | D |
Explanation of responses
- F1The shares underlying the option vest in equal quarterly installments over 16 quarters from January 17, 2017, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. This option is subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer.